OncoMatch/Clinical Trials/NCT06435260
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Is NCT06435260 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Camrelizumab+chemotherapy for pancreatic cancer.
Treatment: Camrelizumab+chemotherapy — The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of Borderline Resectable/locally advanced pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Kidney function
No kidney diseases
Liver function
No liver diseases
Cardiac function
No myocarditis, coronary heart disease, other cardiovascular and cerebrovascular diseases
no history of ... myocarditis, coronary heart disease, other cardiovascular and cerebrovascular diseases, ... liver and kidney diseases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06435260 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages